# of Displayed Technologies: 1 / 1


Categories

Unleashing the Power of Radiotherapy - Enhancing Tumor Oxygenation with Next-Gen Radiosensitizers
TS-062384 — , T2018-092, T2018-354, & T2020-216 This technology provides novel radiosensitizer compounds that are derivatives of papaverine designed to enhance tumor oxygenization without PDE-related side effects.
Papaverine is an FDA-approved phosphodiesterase 10A (PDE10A) inhibitor and its clinical use is due to these effects on blood pressure and vascular tone. However, it was found to also be a potent inhibitor of mitochondrial complex I. Papaverine’s mitochondrial complex I inhibition has been sho…
  • College: College of Medicine (COM)
  • Inventors: Denko, Nicholas; Benej, Martin; Haines, Ben; Mitton-Fry, Mark
  • Licensing Officer: Schultz, Teri

Loading icon